Healthcare Providers and Services
Company Overview of Massachusetts General Hospital Inc.
Massachusetts General Hospital Inc. operates a general hospital that provides diagnostic and therapeutic care services in Boston. It offers medical care services in the areas of allergy and immunology, blood, bones, muscles and joints, brain, spine and nervous system, cancer, circulatory, dermatology, digestive disorders, endocrine, diabetes and metabolism, heart, infectious diseases, kidneys, lungs, mouth, teeth and face, obstetrics and gynecology, psychiatry, rheumatology, surgery, urology, and transplantation and vascular medicine. The company also provides pediatric health care services; and patient and family support services, which include child care, emotional and support programs, ex...
55 Fruit Street
Boston, MA 02114
Founded in 1811
Key Executives for Massachusetts General Hospital Inc.
Chairman of Massachusetts General Physicians Organization and Chief Executive Officer Massachusetts General Physicians Organization
Chief of Dermatology Service
Chairman of the Chiefs' Council
Compensation as of Fiscal Year 2013.
Massachusetts General Hospital Inc. Key Developments
ICT Automatisering Forms Strategic Partnership with Massachusetts General Hospital
Nov 4 13
ICT Automatisering has formed a strategic partnership with Massachusetts General Hospital, or MGH, in Boston, the US, to reportedly optimize the workflow in the radiation therapy department. ICT will use technology developed by its partner InterSystems to integrate the radiation therapy systems of the various providers in the new central department reference index, developed by ICT itself. This will result in a much better workflow, more efficient use of expensive equipment and faster and better care for patients.
Retrosense Therapeutics Announces Exclusive Option to Intellectual Property Covering Vision Augmentation from Massachusetts General Hospital
Mar 27 13
RetroSense Therapeutics announced that it has entered into an option agreement with Massachusetts General Hospital (Massachusetts General Hospital Inc.) under which RetroSense has the right to an exclusive, worldwide license to the patent application 'Method for Augmenting Vision in Persons Suffering from Photoreceptor Cell Degeneration'. The optioned patent application centers on methods for restoring or improving vision using optogenetic approaches. The research, focused on a protein known as melanopsin, was conducted by Richard Masland, PhD, director of the Cellular Neurobiology Laboratory in the MGH Department of Neurosurgery. Optogenetics refers broadly to means of conferring light sensitivity to cells that were not previously, or natively light sensitive. It is proven science optogenetics was Nature's Method of the Year in 2010. By applying optogenetics to retinas in which photoreceptors (rods and cones) have degenerated, RetroSense is conferring new light sensitivity to the retina, with the expectation of improved or restored vision.
Blueprint Medicines Corp. Announces First Collaboration with Wellcome Trust Sanger Institute and Massachusetts General Hospital Cancer Center
Mar 19 13
Blueprint Medicines Corp. announced its first collaboration with Wellcome Trust Sanger Institute and the Massachusetts General Hospital Cancer Center. The collaboration will focus on a large collection of Blueprint's next-generation, highly-selective kinase inhibitor compounds, utilizing the Sanger Institute and Mass. General's extensive human cancer cell line panel that will enable discoveries of novel cancer targets and new cancer dependencies. In collaboration with the Massachusetts General Hospital Cancer Center, the Sanger Institute has built an extensive panel of over 1,200 cancer cell lines used to screen compounds and evaluate their activity toward particular cancer targets. Blueprint Medicines will contribute kinase inhibitors, addressing more than 60 unique targets, with unmatched selectivity for this collaboration. The company is building a robust pre-clinical pipeline of novel programs that are generated by its proprietary genomics platform and pioneering kinase inhibitor library. Utilizing its broad kinase inhibitor library will enable the identification of novel targets that will form the basis of new programs.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|